Premium
Recent progress of national banking project on homozygous HLA ‐typed induced pluripotent stem cells in S outh K orea
Author(s) -
Rim Yeri Alice,
Park Narae,
Nam Yoojun,
Ham DongSik,
Kim JiWon,
Ha HyeYeong,
Jung JiWon,
Jung Seung Min,
Baek In Cheol,
Kim SuYeon,
Kim TaiGyu,
Song Jihwan,
Lee Jennifer,
Park SungHwan,
Chung NakGyun,
Yoon KunHo,
Ju Ji Hyeon
Publication year - 2018
Publication title -
journal of tissue engineering and regenerative medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.835
H-Index - 72
eISSN - 1932-7005
pISSN - 1932-6254
DOI - 10.1002/term.2578
Subject(s) - induced pluripotent stem cell , reprogramming , human leukocyte antigen , population , somatic cell , stem cell , biology , immunology , microbiology and biotechnology , antigen , cell , genetics , medicine , embryonic stem cell , gene , environmental health
Abstract Induced pluripotent stem cells (iPSCs) can be generated by introducing several factors into mature somatic cells. Banking of iPSCs can lead to wider application for treatment and research. In an economical view, it is important to store cells that can cover a high percentage of the population. Therefore, the use of homozygous human leukocyte antigen‐iPSCs (HLA‐iPSCs) is thought as a potential candidate for effective iPSC banking system for further clinical use. We screened the database stored in the Catholic Hematopoietic Stem Cell Bank of Korea and sorted the most frequent homozygous HLA types of the South Korean population. Blood cells with the selected homozygous HLA types were obtained and transferred to the GMP facility in the Catholic Institute of Cell Therapy. Cells were reprogrammed to iPSCs inside the facility and went through several quality controls. As a result, a total of 13 homozygous GMP‐grade iPSC lines were obtained in the facility. The generated iPSCs showed high pluripotency and normal karyotype after reprogramming. Five HLA‐homozygous iPSCs had the type that was included in the top five most frequent HLA types. Homozygous HLA‐iPSCs can open a new opportunity for further application of iPSCs in clinical research and therapy.